Elsevier

Clinical Therapeutics

Volume 19, Issue 1, January–February 1997, Pages 96-112
Clinical Therapeutics

Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome

https://doi.org/10.1016/S0149-2918(97)80077-XGet rights and content

Abstract

A decision analytic study was conducted using computer simulation to project the outcomes in a simulated cohort of patients whose treatment for back surgery had failed. The objective of this study was to estimate the direct cost of intrathecal morphine therapy (IMT) delivered via an implantable pump relative to alternative therapy (medical management) over a 60-month course of treatment. IMT administered by way of an implantable pump can provide effective pain relief for selected patients whose less invasive treatment modalities have failed. Previous research suggested that a pump implant is less costly than alternative methods providing comparable analgesia for treatment exceeding 12 to 18 months. However, those analyses did not include the cost of complications or pump replacement. Scenarios representing the course of IMT, devised by a panel of experts, were represented as treatment pathways in a Monte Carlo simulation. Adverse event rates were drawn from published data supplemented by expert judgment. Direct costs were based on a health insurer paid claims perspective (direct costs) discounted at a 5% annual rate. The cost-effectiveness of IMT was calculated based on a report of 65% to 81% “good to excellent” pain relief relative to alternative (medical) management. With both adverse event probabilities and costs set at most likely (base case) values, the expected total cost of IMT over 60 months was $82,893 (an average of $1382 per month). In a sensitivity analysis, the best case (low adverse event rate, low cost) estimate was $53,468 ($891/mo), whereas the worst case (high adverse event rate, high cost) estimate was $125,102 ($2085/mo). Cost-effectiveness estimates ranged from $7212 (best case) to $12,276 (worst case) per year of pain relief. Results from a computer simulation designed to collect the costs not included in previous empiric research indicate that IMT appears to be cost-effective when compared with alternative (medical) management for selected patients when the duration of therapy exceeds 12 to 22 months

References (28)

  • R Leitman et al.
    (1994)
  • JW Frymoyer et al.

    An overview of the incidences and costs of low back pain

    Orthop Clin North Am

    (1991)
  • National Center for Health Statistics

    (1990)
  • MD Bedder et al.

    Cost analysis of two implantable narcotic delivery systems

    J Pain Symptom Manage

    (1991)
  • AL Hillman et al.

    Avoiding bias in the conduct of and reporting of cost-effectiveness research sponsored by pharmaceutical companies

    NEJM

    (1991)
  • JA Paice et al.

    Intraspinal drug therapy

    Nurs Clin North Am

    (1991)
  • ES Krames

    Intrathecal infusional therapies for intractable pain: Patient management guidelines

    J Pain Symptom Manage

    (1993)
  • ES Krames et al.

    Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine

    J Pain Symptom Manage

    (1993)
  • JA Paice et al.

    Altered sexual function and decreased testosterone in patients receiving intraspinal opioids

    J Pain Symptom Manage

    (1994)
  • SJ Hassenbusch et al.

    Constant infusion of morphine for intractable cancer pain using an implanted pump

    J Neurosurg

    (1990)
  • JA Paice et al.
    (1994)
  • Neurological Division. Returned Product Analysis

    (1994)
  • SJ Hassenbusch et al.
    (1994)
  • Cited by (110)

    • The Development of Algorithms for Pain Care Including Neuromodulation Therapies: Introducing the SAFE Principles

      2018, Neuromodulation: Comprehensive Textbook of Principles, Technologies, and Therapies, Second Edition: Volume 1-3
    • Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity

      2015, European Journal of Pharmacology
      Citation Excerpt :

      Previous study, conducted to evaluate the efficacy of intrathecal and intraperitoneal injections of morphine on neuropathic pain induced by T13 spinal hemisection in rats, demonstrated that higher dose of systemic morphine is needed to produce the same anti-allodynic effect reached with the i.t. injection (Kim et al., 2003). The i.t. route offers a safe and effective alternative when i.v. or oral opioids are only partially effective (Grady and Raphael, 2008) e.g. for the management of chronic non-cancer pain (Biggs et al., 2011; De Lissovoy et al., 1997; Hassenbusch et al., 1997). Recent studies support the long-term effectiveness following 3 years of treatment (Duarte et al., 2012).

    • Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management: A retrospective analysis of 365 patients

      2015, Neuromodulation
      Citation Excerpt :

      While they are currently in widespread use, the real-world cost of implanting and maintaining functioning intrathecal drug delivery systems has not been quantified, especially in a long-term cohort. De Lissovoy et al. quantified the costs of implanting and maintaining an intrathecal drug delivery system in a modeled population where adverse event rates were drawn from published data supplemented by experts’ estimates of complication rates (1997) (2). The cumulative cost incurred by one real-world cohort of patients in Saskatchewan was found to total 29,410 Canadian dollars when assessed over a 5-year period (7).

    • Interventional therapies for chronic low back pain

      2014, Neuromodulation
      Citation Excerpt :

      Contraindications to pump implant include common surgical contraindications such as infection and anticoagulation. The most frequent indication for intrathecal delivery of opioids for noncancer chronic pain is FBSS (127,131–134). Intrathecal infusion with implantable pumps has been used successfully in treatment of back pain due to osteoporosis and vertebral compression fractures (135,136).

    View all citing articles on Scopus
    View full text